Editions:  Austria · Denmark · France · Germany · Italy · Norway · Spain · Sweden · Switzerland
Advertisement

Actelion to appeal damages order

Share this article

09:26 CEST+02:00

Swiss biotechnology group Actelion said Wednesday that it would appeal against $547 million in damages awarded by a California court to Japanese company Asahi Kasei Pharma.

Actelion said in a statement that it had also filed a short-term court motion to try to pare down compensation, partly due to previous arbitration on the issue.

"The company will file appropriate further post-trial motions and will appeal the entire judgment," it added.

It believes the ruling is "neither supported by the facts nor is it correct as a matter of law."

The dispute dates back to November 2008 when Asahi filed suit over the cancellation of an agreement with Actelion subsidiary Cotherix to licence and develop a drug compound called fasudil.

Its current motion is asking for a choice to be made between damages of $358.95 million for alleged lost profits or $187.4 million in alleged development costs; and for an additional deduction of $78.4 million due to previous arbitration.

The biotech firm noted that punitive damages of 30 million dollars had also been awarded against some company executives.

Get notified about breaking news on The Local

Share this article

Advertisement
Advertisement
Advertisement
Jobs
Click here to start your job search
Advertisement
Advertisement

Popular articles

Advertisement
Advertisement